This aberrant iNKT cell activation was correctable by simultaneous addition of the exogenous CD1d ligand α-GalCer and IL-12, and allowed iNKT cells to produce IFNγ in response to tumor cells. The gene discussed is IFNG; the disease is neoplasm.